BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 31646996)

  • 1. A phosphodiesterase 5 inhibitor, tadalafil, suppresses stromal predominance and inflammation in a rat model of nonbacterial prostatitis.
    Sugimoto M; Zhang X; Ueda N; Tsunemori H; Taoka R; Hayashida Y; Hirama H; Miyauchi Y; Matsuoka Y; Naito H; Osaki Y; Kekehi Y
    BMC Urol; 2019 Oct; 19(1):99. PubMed ID: 31646996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The phytotherapeutic agent, eviprostat, suppresses stromal proliferation and inflammation even after establishment of nonbacterial prostatitis in the rat prostate.
    Shibuya S; Xia Z; Sugimoto M; Ueda N; Haba R; Kakehi Y
    Urology; 2014 Mar; 83(3):528-34. PubMed ID: 24581515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic pelvic pain and prostate inflammation in rat experimental autoimmune prostatitis: Effect of a single treatment with phosphodiesterase 5 inhibitors on chronic pelvic pain.
    Kurita M; Yamaguchi H; Okamoto K; Kotera T; Oka M
    Prostate; 2018 Nov; 78(15):1157-1165. PubMed ID: 30009466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The anti-inflammatory effect of montelukast, a cysteinyl leukotriene receptor-1 antagonist, against estradiol-induced nonbacterial inflammation in the rat prostate.
    Said MM; Bosland MC
    Naunyn Schmiedebergs Arch Pharmacol; 2017 Feb; 390(2):197-205. PubMed ID: 27909742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Voiding behavior and chronic pelvic pain in two types of rat nonbacterial prostatitis models: Attenuation of chronic pelvic pain by repeated administration of tadalafil.
    Yamaguchi H; Kurita M; Okamoto K; Kotera T; Oka M
    Prostate; 2019 Apr; 79(5):446-453. PubMed ID: 30549073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of tadalafil on chronic pelvic pain and prostatic inflammation in a rat model of experimental autoimmune prostatitis.
    Okamoto K; Kurita M; Yamaguchi H; Numakura Y; Oka M
    Prostate; 2018 Jul; 78(10):707-713. PubMed ID: 29577372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the phytotherapeutic agent Eviprostat on 17beta-estradiol-induced nonbacterial inflammation in the rat prostate.
    Oka M; Ueda M; Oyama T; Kyotani J; Tanaka M
    Prostate; 2009 Sep; 69(13):1404-10. PubMed ID: 19489033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of inflammation and aging on macrophage inhibitory cytokine-1 gene expression in rat ventral prostate.
    Taniguchi S; Taoka R; Inui M; Sugimoto M; Kakehi Y
    Urology; 2009 Feb; 73(2):410-4. PubMed ID: 18929399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.
    Gacci M; Andersson KE; Chapple C; Maggi M; Mirone V; Oelke M; Porst H; Roehrborn C; Stief C; Giuliano F
    Eur Urol; 2016 Jul; 70(1):124-133. PubMed ID: 26806655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tadalafil is sufficiently effective for severe chronic prostatitis/chronic pelvic pain syndrome in patients with benign prostatic hyperplasia.
    Hiramatsu I; Tsujimura A; Soejima M; Yoshiyama A; Nagashima Y; Ishikawa K; Uesaka Y; Nozaki T; Ogishima T; Shirai M; Mitsuhashi I; Sugimura S; Mizuno T; Noto K; Shigeta Y; Takasu J; Honda S; Iwata S; Horie S
    Int J Urol; 2020 Jan; 27(1):53-57. PubMed ID: 31587411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of a single treatment with tadalafil on blood flow in lower urinary tract tissues in rat models of bladder overdistension/emptying and abdominal aorta clamping/release.
    Yoshinaga R; Kawai Y; Oka M; Fuchikami C; Oyama T
    Eur J Pharmacol; 2015 May; 754():92-7. PubMed ID: 25697472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do baseline estrogen and testosterone affect lower urinary tract symptoms (LUTS) prior to or after pharmacologic treatment with tadalafil?
    Egan KB; Miner MM; Suh M; McVary K; Ni X; Roehrborn CG; Wittert G; Wong DG; Rosen RC
    Andrology; 2015 Nov; 3(6):1165-72. PubMed ID: 26452447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS.
    Vignozzi L; Gacci M; Cellai I; Morelli A; Maneschi E; Comeglio P; Santi R; Filippi S; Sebastianelli A; Nesi G; Serni S; Carini M; Maggi M
    Prostate; 2013 Sep; 73(13):1391-402. PubMed ID: 23765639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bladder function in 17β-estradiol-induced nonbacterial prostatitis model in Wistar rat.
    Matsumoto S; Kawai Y; Oka M; Oyama T; Hashizume K; Wada N; Hori J; Tamaki G; Kita M; Iwata T; Kakizaki H
    Int Urol Nephrol; 2013 Jun; 45(3):749-54. PubMed ID: 23616059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective effects of tadalafil on prostatic hyperplasia in spontaneously hypertensive rats.
    Shimizu S; Nagao Y; Kataoka T; Kamada S; Shimizu T; Higashi Y; Saito M
    Eur J Pharmacol; 2020 Sep; 882():173313. PubMed ID: 32603695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tadalafil Improves Symptoms, Erectile Function and Quality of Life in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (KYU-PRO Study).
    Takahashi R; Miyazato M; Nishii H; Sumino Y; Takayama K; Onzuka M; Oshiro T; Saito S; Fujimoto N; Mimata H; Eto M
    Low Urin Tract Symptoms; 2018 Jan; 10(1):76-83. PubMed ID: 29341501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomized, placebo-controlled clinical studies.
    Porst H; Oelke M; Goldfischer ER; Cox D; Watts S; Dey D; Viktrup L
    Urology; 2013 Sep; 82(3):667-73. PubMed ID: 23876588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphodiesterase type 5 inhibitor attenuates chronic ischemia-induced prostatic hyperplasia in a rat model.
    Fujii S; Yamashita S; Hayashi N; Goto T; Koyama J; Sato T; Shimada S; Kawasaki Y; Izumi H; Kawamorita N; Mitsuzuka K; Ito A; Arai Y
    Prostate; 2019 Apr; 79(5):536-543. PubMed ID: 30593704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of the phytotherapeutic agent Eviprostat on inflammatory changes and cytokine production in a rat model of nonbacterial prostatitis.
    Tsunemori H; Sugimoto M; Xia Z; Taoka R; Oka M; Kakehi Y
    Urology; 2011 Jun; 77(6):1507.e15-20. PubMed ID: 21624608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the phosphodiesterase 5 inhibitor Tadalafil on bladder function in a rat model of partial bladder outlet obstruction.
    Kawai Y; Oka M; Yoshinaga R; Fuchikami C; Oyama T
    Neurourol Urodyn; 2016 Apr; 35(4):444-9. PubMed ID: 25703926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.